Background: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted
global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the …

Abstract Pyruvate dehydrogenase kinase-1 (PDK1), a key metabolic enzyme involved in
aerobic glycolysis, is highly expressed in many solid tumors. Small molecule compound …

Abstract Dickkopf-1 (Dkk1)'s dysregulation has been implicated in the pathogenesis of a
variety of cancers. It is part of the Dkk family of proteins that includes Dkk2, Dkk3 and Dkk4 …

Abstract Pyruvate dehydrogenase kinase 3 (PDK3) is a mitochondrial protein, has recently
been considered as a potential pharmacological target for varying types of cancer. Here, we …

Hematopoietic progenitor kinase 1 (HPK1) is an important negative regulator in T-cell
receptor signaling and as a promising key target for immunotherapy. Herein, based on the …

Deregulation of cyclin-dependent kinase 2 (CDK2) and its activating partners, cyclins A and
E, is associated with the pathogenesis of a myriad of human cancers and with resistance to …

Because malignant cells have altered, usually accelerated, energy consumption, targeting
metabolic signaling represents a prevailing strategy for tumor therapy. Phosphoinositide …

Targeting KRAS-PDEδ protein–protein interactions with small molecules represents a
promising opportunity for developing novel antitumor agents. However, current KRAS-PDEδ …

Objective Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA),
few effective therapies and high mortality make this disease a prime model for advancing …

Growth factor binding events to receptor tyrosine kinases result in activation of
phosphatidylinositol 3‐kinase (PI3K), and activated PI3K generates the membrane‐bound …